Internship
Ultima Genomics
201-500 employees
High-throughput genomic sequencing services
Compensation Overview
$30 - $36/hr
Fremont, CA, USA
Internship requires working onsite full-time (40 hours per week) for at least 8 weeks during summer 2025.
Upload your resume to see how it matches 9 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
- Currently a student in an accredited degree program pursuing a bachelor’s or master’s degree in Computer Science, Engineering, or Physics
- At least 1 year of programming experience
- Have an overall cumulative GPA of 3.00 or higher
- Ability to work onsite and work full-time (40 hours per week) for at least 8 weeks during summer 2025
- Self-motivated, detail-oriented, willing to learn, and interested in working in a team environment
- Great work ethic and an enthusiasm for problem-solving
- Good presentation, writing and communication skills
- Strong organizational and analytical skills
- Work in a fast-paced cross-functional, technologically advanced corporate environment in an internship program focused on developing individual engineers capable of pursuing careers in biotech
- Improve your industry knowledge through a collaborative work environment
- Develop internal facing analytics tools
- Develop statistical models of system performance
- Experience with statistics and data science preferred
Ultima Genomics focuses on improving human health through advanced genomic sequencing technologies. The company processes large amounts of genetic data to provide insights into human biology and diseases. Its clients include academic researchers, pharmaceutical companies, and healthcare providers who need accurate genomic data for their work. Ultima Genomics stands out with its unique sequencing architecture that enhances the breadth, depth, and frequency of data collection. This means they can gather extensive information from samples, detect small genetic variations, and perform routine tests for early disease detection. The company generates revenue by offering these sequencing services and collaborates with other organizations to expand genomic information, facilitating important discoveries in health. The goal of Ultima Genomics is to enable researchers and healthcare professionals to achieve breakthroughs in understanding and treating diseases.
Company Size
201-500
Company Stage
Late Stage VC
Total Funding
$604.2M
Headquarters
Newark, New Jersey
Founded
2016
Simplify's Take
What believers are saying
- UG 100 platform enables $80 genome, making sequencing more accessible and affordable.
- Collaboration with Labcorp enhances cancer diagnostics through advanced sequencing technologies.
- Partnership with Hartwig Medical aims to make whole genome sequencing affordable for cancer diagnostics.
What critics are saying
- Competition from Illumina threatens Ultima's market share in genomic sequencing.
- High costs of next-generation sequencing technologies limit widespread adoption.
- Reliance on partnerships poses risks if partners develop competing technologies.
What makes Ultima Genomics unique
- Ultima Genomics offers revolutionary sequencing architecture enhancing data breadth, depth, and frequency.
- UG 100 Solaris platform increases output by 50% and reduces costs by 20%.
- Partnerships with biopharma companies for large-scale projects like the UK Biobank study.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
Paid Holidays
Paid Vacation
Employee Assistance Program
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↑ 0%2 year growth
↑ 0%Commercial launch of UG 100 Solaris which includes new chemistry, software, and simplified workflows for the UG 100 sequencing platform, now with expanded applications support and integration with leading 'omics' technologies. Over 50% increase in output to 10 to 12 billion reads per wafer and pricing reduced by 20% to $0.24 per million reads, enabling the $80 genome. Increased sensitivity with 5X yield improvement for the SNVQ60 ppmSeq™ mode enabling 30X coverage from as little as 2 nanograms of DNA (1/5th of the cfDNA found in a standard tube of blood)
Compugen enhances its AI/ML predictive Computational Discovery platform, Unigen(TM) with Ultima Genomics' Single Cell Genomics sequencing technology.
Genome Sequencing Cost CurveFor most of the history of medicine, doctors have been limited to observing symptoms and trying to alleviate them. This has been especially true for non-infectious diseases stemming from dysfunction in the body, including genetic diseases.With the discovery of DNA structure and function, awarded the 1962 Nobel Prize in Medicine , we started to have a better understanding of how the biological system truly works. PCR technology, awarded the 1993 Nobel Prize in Medicine , would open new ways to analyze it.This further expanded when full genomes started to be sequenced. The first human genome was sequenced in 2003 after 13 years of hard work, for a cost of $3B. Quickly, full-genome sequencing started to become cheaper and cheaper. By 2007, it would cost “only” $1M to sequence a full genome
World's Most Comprehensive Protein Study Highlights Ultima's Commitment to Unlocking the Power of Genomics at ScaleFREMONT, Calif., Jan. 9, 2025 /PRNewswire/ -- Ultima Genomics, Inc., a developer of an ultra-high throughput next-generation sequencing (NGS) platform, today announced that its UG 100™ was selected as the sequencing platform to enable UK Biobank's unprecedented protein study, which will be the world's largest and most comprehensive proteomics study to date. The UG 100™ was selected by a consortium of 14 leading biopharma companies funding the UK Biobank Pharma Proteomics Project and will be used in conjunction with Thermo Fisher Scientific's Olink® Explore HT proteomics platform to play a central role in this first-of-its-kind effort in understanding disease progression and advancing personalized medicine. This unparalleled project aspires to quantify more than 5,400 protein markers across 600,000 samples, including those from half a million UK Biobank participants and 100,000 second samples taken from a subset of these participants across different time points (spanning up to 15 years). This will allow researchers to explore a unique and unprecedented database. The UK Biobank project, announced today, aims to investigate how fluctuations in protein levels during mid- to late-life may influence disease progression and overall health
Myriad Genetics has announced a collaboration with Ultima Genomics to evaluate the potential of the UG 100 sequencing platform and ppmSeq technology in advancing clinical tests in oncology and reproductive genomics.